Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers

M. Cánovas, J. Delgadillo, F. Torres, N. Riba, J. Cebrecos, P. Pelagio, F. Cabré

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Objective: The objective of the study was to evaluate bioequivalence of two strengths (1 and 2 mg) of oral risperidone tablet formulations (test product manufactured by Vita-Invest, S.A., Barcelona, Spain, reference product manufactured by Janssen-Cilag Ltd., UK). Subjects and methods: In each of the 2 studies, 30 healthy volunteers were administered 1 or 2 mg, respectively, of test or reference formulation under fasting conditions in an open, two-way crossover, controlled, randomized and single-site fashion. Blood withdrawal was performed prior to dosing as well as 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 5 h, 8 h, 12 h, 16 h, 24 h, 48 h, 72 h, and 96 h after drug administration. Plasma concentrations of risperidone and its metabolite 9-hydroxy-risperidone were analyzed using LC/MS/MS. Descriptive data of AUC0-t, AUC0-α, Cmax, and Cmax/AUC0-α were log-transformed to evaluate bioequivalence based on the ratios of the geometric means of test and reference formulations. tmax was analyzed using nonparametric methods. Results: The results show that in both studies, 1 and 2 mg formulations, the 90% confidence intervals for the geometric means ratios of the test and reference products for both the parent compound risperidone and its metabolite 9- hydroxy-risperidone were all within the bioequivalence acceptance criteria of 0.80 - 1.25 of the European CPMP and the US FDA guidelines, with the exception of tmax for risperidone parent compound in the 2 mg formulation, which was slightly suprabioequivalent for test formulation. Conclusion: This study demonstrated the bioequivalence between the test and the reference product of risperidone of both 1 and 2 mg formulations. Both formulations of each strength may, therefore, be prescribed interchangeably. © 2009 Dustri-Verlag Dr. K. Feistle.
Original languageEnglish
Pages (from-to)124-131
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume47
Issue number2
DOIs
Publication statusPublished - 1 Jan 2009

Keywords

  • Bioequivalence
  • Healthy subjects
  • Pharmacokinetics
  • Risperidone
  • Tablet

Fingerprint Dive into the research topics of 'Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers'. Together they form a unique fingerprint.

Cite this